Hepatitis C

1234567891011121314151617
Across
  1. 2. phrase relating to DAA coverage of all genotypes
  2. 4. DAAs are contraindicated with these CYP strong inducers
  3. 6. scarring of the liver
  4. 9. first line treatment class of HCV
  5. 12. use of this drug class with Epclusa is not recommended
  6. 13. lab that is required throughout course of therapy dependent on patient risk factors
  7. 15. black box warning of DAAs
  8. 16. lab that is drawn 12 weeks after therapy completion
  9. 17. brand name of glecaprevir/pibrentasvir
Down
  1. 1. previous treatment option for HCV that has fallen out of favor
  2. 3. DAA mechanism class that must be taken with food
  3. 5. inflammation of the liver
  4. 7. transmission of HCV
  5. 8. combination with this drug class can increase risk of myopathy
  6. 10. sofosbuvir mechanism of action
  7. 11. treatment duration of Epclusa
  8. 14. common side effect of DAAs
  9. 15. type of hepatitis that does not have vaccine coverage